Surgical simulation steps into a new phase in ophthalmology

Tern plc

In the niche but technically demanding world of ophthalmology, a new approach to training is gaining ground. The traditional reliance on live surgical observation and supervised repetition is being supplemented, and in some cases, pre-empted, by immersive extended reality. At the centre of this evolution is a structured rollout model that reframes simulation as a progressive system of implementation.

Fundamental XR has laid out a clear, phased framework for XR adoption, beginning with pilot testing and moving deliberately through infrastructure deployment, staff onboarding, content calibration, and outcome tracking. This matters because while extended reality has been circulating in healthcare discussions for years, what has often been missing is a replicable model for institutional uptake, something that works beyond a showcase or demo setting.

What makes this opportunity distinctive is that it bypasses much of the hype surrounding general-use XR platforms. Instead, it targets a clear pain point, surgical training bottlenecks, with a solution that is already seeing traction across professional institutions.

Developing and maintaining specialty-specific content, adapting to new surgical techniques and staying aligned with evolving training standards all require sustained investment. But these same factors create defensible barriers to entry. In fields like ophthalmology, where each device or procedure has unique requirements, the demand for high-fidelity simulation remains acute, and unlikely to be met by generalist solutions.

More importantly, this model may not stay confined to one field. If the implementation roadmap proves successful in ophthalmology, there is a clear logic to extending it into other surgical specialities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search